IP Library Granted Patent US 8,044,100
Granted Patent B2
US 8,044,100 · App. 11/316,693 · Granted Oct 25, 2011

Methods and compositions for treating amyloid-related diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,044,100
App. No.
11/316,693
Granted
Oct 25, 2011
Kind
B2
Abstract

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Claims (22)

1. A compound of the formula (XII):

wherein:

R h is hydrogen or unsubstituted alkyl;

R i is unsubstituted C 2 -C 7 alkyl;

R j , R k , R m , R n , and R o are each independently hydrogen or unsubstituted alkyl;

X + is hydrogen, a cationic group, or an ester-forming group; and

t 1 and t 2 are each a single bond or a pharmaceutically acceptable salt, ester, or prodrug thereof.

2. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt or ester, thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 .

4. A pharmaceutical composition comprising a compound selected from the group consisting of:

and a pharmaceutically acceptable carrier.

5. The compound of claim 1 , wherein R h is hydrogen.

6. The compound of claim 5 , wherein R j , R m , and R o are each hydrogen.

7. The compound of claim 5 , wherein R j , R k , R m , R n and R o are each hydrogen.

8. The compound of claim 7 , wherein R i is ethyl, propyl, butyl, pentyl, hexyl or heptyl.

9. The compound of claim 1 , wherein said compound has the structure:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 9 , wherein said compound has the structure:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 9 , wherein said compound has the structure:

or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Jul 19, 2012
From: BELLUS HEALTH INC.
To: BHI LIMITED PARTNERSHIP
Reel/Frame 028587/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2011
From: BELLUS HEALTH (INTERNATIONAL) LIMITED
To: BELLUS HEALTH INC.
Reel/Frame 026936/0012 →
CHANGE OF NAME Recorded Jul 31, 2008
From: NEUROCHEM (INTERNATIONAL) LIMITED
To: BELLUS HEALTH (INTERNATIONAL) LIMITED
Reel/Frame 021373/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2006
From: KONG, XIANQI; WU, XINFU; BOUZIDE, ABDERRAHIM; VALADE, ISABELLE; MIGNEAULT, DAVID; GERVAIS, FRANCINE; DELORME, DANIEL; BACHAND, BENOIT; ATFANI, MOHAMED; LEVESQUE, SOPHIE; SAMIM, BITA
To: NEUROCHEM (INTERNATIONAL) LIMITED
Reel/Frame 017760/0337 →